Evidence map›Paper›PMID 35757481›Full record

ArticleBioMed research international2022

An Ideal Approach for Enhancing 5-Fluorouracil Anticancer Efficacy by Nanoemulsion for Cytotoxicity against a Human Hepatoma Cell Line (HepG2 Cells).

Jamal Moideen Muthu Mohamed, Fazil Ahamad, Mohamed El-Sherbiny, Hasnaa Ali Ebrahim, Mohamed Ahmed Eladl, Amal F Dawood, S T Sheik Abdul Khader, Karuppaiyan Kavitha, Dawit Mamiru Teressa

RetractedAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Polymeric ethosomal gel loaded with nimodipine: Optimisation, pharmacokinetic and histopathological analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jamal Moideen Muthu MohamedCollege of Pharmacy, Shri Indra Ganesan Institute of Medical Science, Manikandam, Tiruchirapalli, 620012 Tamil Nadu, India.
Fazil AhamadDepartment of Anesthesia Technology, College of Applied Medical Sciences in Jubail, Imam Abdulrahman Bin Faisal University, P.O. Box 4030, Jubail, Saudi Arabia.
Mohamed El-SherbinyDepartment of Basic Medical Sciences, College of Medicine, AlMaarefa University, P.O. Box 71666, Riyadh 11597, Saudi Arabia.ORCID https://orcid.org/0000-0002-0814-1743
Hasnaa Ali EbrahimDepartment of Basic Medical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.ORCID https://orcid.org/0000-0001-9194-9649
Mohamed Ahmed EladlDepartment of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, UAE.
Amal F DawoodDepartment of Basic Medical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
S T Sheik Abdul KhaderDepartment of Pharmaceutical Technology, BIT Campus, Anna University, Tiruchirappalli, 620024 Tamil Nadu, India.
Karuppaiyan KavithaDepartment of Pharmaceutical Technology, BIT Campus, Anna University, Tiruchirappalli, 620024 Tamil Nadu, India.ORCID https://orcid.org/0000-0002-7362-8507
Dawit Mamiru TeressaDepartment of Chemical Engineering, College of Biological and Chemical Engineering, Addis Ababa Science and Technology University, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0001-5270-8252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The core objectives of the research were to prepare 5-fluorouracil nanoemulsion (FU-NE) and to evaluate the physiochemical properties and to study the i

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNanoparticlesCell Line, TumorFluorouracilHep G2 CellsHumansParticle SizeFluorouracil

Identifiers

PMID35757481
PMCPMC9232351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.